Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIOVAS biologics trial in refractory non-ANCA-associated vasculitis
2019-003964-30Phase 2Unknown
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of infliximab, rituximab and tocilizumab in vasculitis, large-vessel vasculitis (LVV), giant cell arteritis (GCA) and 1 more (4 arms), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoint: Time to treatment failure. Status: unknown.
02
Drugs
infliximabrituximabtocilizumab
03
Conditions
vasculitislarge-vessel vasculitis (LVV)giant cell arteritis (GCA)Takayasu arteritis (TAK)
Beyond the preview
Go deeper on 2019-003964-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003964-30.